[Read more...]
Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WorldSymposium
[Read more...]
Passage Bio Announces Closure of Krabbe Disease Program
[Read more...]
Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease
[Read more...]
Passage Bio Receives European Commission Orphan Designation for PBKR03 for Treatment of Krabbe Disease
[Read more...]
U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders
[Read more...]
FDA Fast Track, ODD, and RPDD Designations for FBX-101 Gene Therapy for Patients with Krabbe Disease
[Read more...]
FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options
[Read more...]
Passage Bio’s PBKR03 Receives Orphan Drug and Rare Pediatric Disease Designations from FDA for Treatment of Krabbe Disease
[Read more...]
Passage Bio Announces Third Gene Therapy Development Program in Krabbe Disease and Supports Million Dreams Fundraising Gala
[Read more...]